S&P 500   4,203.26 (-0.05%)
DOW   32,910.68 (-0.55%)
QQQ   351.61 (+0.92%)
AAPL   177.50 (+1.18%)
MSFT   333.09 (+0.06%)
META   265.40 (+1.28%)
GOOGL   124.41 (-0.16%)
AMZN   121.89 (+1.48%)
TSLA   200.87 (+3.99%)
NVDA   410.63 (+5.44%)
NIO   7.53 (-2.21%)
BABA   78.65 (-2.87%)
AMD   127.25 (+0.17%)
T   15.62 (+0.77%)
F   12.68 (+4.88%)
MU   73.27 (-0.89%)
CGC   0.86 (-1.55%)
GE   101.82 (-0.90%)
DIS   87.61 (-0.77%)
AMC   4.57 (-1.51%)
PFE   37.11 (-1.30%)
PYPL   59.60 (-1.03%)
NFLX   396.01 (+4.52%)
S&P 500   4,203.26 (-0.05%)
DOW   32,910.68 (-0.55%)
QQQ   351.61 (+0.92%)
AAPL   177.50 (+1.18%)
MSFT   333.09 (+0.06%)
META   265.40 (+1.28%)
GOOGL   124.41 (-0.16%)
AMZN   121.89 (+1.48%)
TSLA   200.87 (+3.99%)
NVDA   410.63 (+5.44%)
NIO   7.53 (-2.21%)
BABA   78.65 (-2.87%)
AMD   127.25 (+0.17%)
T   15.62 (+0.77%)
F   12.68 (+4.88%)
MU   73.27 (-0.89%)
CGC   0.86 (-1.55%)
GE   101.82 (-0.90%)
DIS   87.61 (-0.77%)
AMC   4.57 (-1.51%)
PFE   37.11 (-1.30%)
PYPL   59.60 (-1.03%)
NFLX   396.01 (+4.52%)
S&P 500   4,203.26 (-0.05%)
DOW   32,910.68 (-0.55%)
QQQ   351.61 (+0.92%)
AAPL   177.50 (+1.18%)
MSFT   333.09 (+0.06%)
META   265.40 (+1.28%)
GOOGL   124.41 (-0.16%)
AMZN   121.89 (+1.48%)
TSLA   200.87 (+3.99%)
NVDA   410.63 (+5.44%)
NIO   7.53 (-2.21%)
BABA   78.65 (-2.87%)
AMD   127.25 (+0.17%)
T   15.62 (+0.77%)
F   12.68 (+4.88%)
MU   73.27 (-0.89%)
CGC   0.86 (-1.55%)
GE   101.82 (-0.90%)
DIS   87.61 (-0.77%)
AMC   4.57 (-1.51%)
PFE   37.11 (-1.30%)
PYPL   59.60 (-1.03%)
NFLX   396.01 (+4.52%)
S&P 500   4,203.26 (-0.05%)
DOW   32,910.68 (-0.55%)
QQQ   351.61 (+0.92%)
AAPL   177.50 (+1.18%)
MSFT   333.09 (+0.06%)
META   265.40 (+1.28%)
GOOGL   124.41 (-0.16%)
AMZN   121.89 (+1.48%)
TSLA   200.87 (+3.99%)
NVDA   410.63 (+5.44%)
NIO   7.53 (-2.21%)
BABA   78.65 (-2.87%)
AMD   127.25 (+0.17%)
T   15.62 (+0.77%)
F   12.68 (+4.88%)
MU   73.27 (-0.89%)
CGC   0.86 (-1.55%)
GE   101.82 (-0.90%)
DIS   87.61 (-0.77%)
AMC   4.57 (-1.51%)
PFE   37.11 (-1.30%)
PYPL   59.60 (-1.03%)
NFLX   396.01 (+4.52%)
Positive News SentimentPositive News
NASDAQ:SEEL

Seelos Therapeutics (SEEL) Stock Forecast, Price & News

$0.85
-0.08 (-8.28%)
(As of 11:16 AM ET)
Compare
Today's Range
$0.83
▼
$0.91
50-Day Range
$0.66
▼
$1.06
52-Week Range
$0.58
▼
$1.52
Volume
363,446 shs
Average Volume
497,282 shs
Market Capitalization
$103.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.33
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Seelos Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
260.4% Upside
$3.33 Price Target
Short Interest
Healthy
4.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

837th out of 1,009 stocks

Pharmaceutical Preparations Industry

418th out of 494 stocks

See Top Rated MarketRank™ Stocks Here

SEEL stock logo

About Seelos Therapeutics (NASDAQ:SEEL) Stock

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

Receive SEEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SEEL Stock News Headlines

May 22, 2023 | finance.yahoo.com
Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences
May 21, 2023 | americanbankingnews.com
FY2023 EPS Estimates for Seelos Therapeutics, Inc. (NASDAQ:SEEL) Decreased by Cantor Fitzgerald
May 30, 2023 | Edge On The Street (Ad)
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
May 17, 2023 | americanbankingnews.com
Seelos Therapeutics (NASDAQ:SEEL) Price Target Cut to $4.00
May 16, 2023 | msn.com
BTIG Maintains Seelos Therapeutics (SEEL) Buy Recommendation
May 16, 2023 | msn.com
Seelos Therapeutics Positive Q1 Financials Make For 'The Most Important Year' In Company's History
May 16, 2023 | msn.com
Cantor Fitzgerald Maintains Seelos Therapeutics (SEEL) Overweight Recommendation
May 16, 2023 | americanbankingnews.com
Seelos Therapeutics (NASDAQ:SEEL) Price Target Cut to $2.00 by Analysts at Cantor Fitzgerald
May 30, 2023 | Edge On The Street (Ad)
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
May 15, 2023 | finanznachrichten.de
Seelos Therapeutics, Inc.: Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
May 15, 2023 | markets.businessinsider.com
Seelos Therapeutics, Inc Q1 Loss decreases, but misses estimates
May 15, 2023 | msn.com
Seelos Therapeutics GAAP EPS of -$0.12 misses by $0.02, revenue of $0.81M
May 15, 2023 | markets.businessinsider.com
BTIG Reaffirms Their Buy Rating on Seelos Therapeutics (SEEL)
May 15, 2023 | finance.yahoo.com
Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
May 13, 2023 | marketwatch.com
2030, Psychedelic Drugs Market: Trend & Outlook
May 5, 2023 | finance.yahoo.com
Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
April 14, 2023 | msn.com
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
April 6, 2023 | msn.com
Unusual Call Option Trade in Seelos Therapeutics (SEEL) Worth $17.57K
April 4, 2023 | finance.yahoo.com
Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program
March 31, 2023 | markets.businessinsider.com
BTIG Remains a Buy on Seelos Therapeutics (SEEL)
March 30, 2023 | marketwatch.com
Psychedelic Medicine Market research Report with Analysis 2023 To 2030
March 30, 2023 | marketwatch.com
Psychedelic Drugs Market Analysis, Industry Report, Trends 2029
March 29, 2023 | finance.yahoo.com
Seelos Therapeutics Announces Business Update on its Key Programs
March 25, 2023 | americanbankingnews.com
Seelos Therapeutics (NASDAQ:SEEL) Price Target Lowered to $4.00 at Benchmark
March 14, 2023 | msn.com
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
March 10, 2023 | marketwatch.com
Seelos Therapeutics Prices Direct Offering With Proceeds of $11.2M
March 10, 2023 | finance.yahoo.com
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
See More Headlines
Receive SEEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SEEL Company Calendar

Today
5/30/2023
Next Earnings (Estimated)
8/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SEEL
CUSIP
N/A
CIK
1017491
Web
www.seelostherapeutics.com
Phone
(646) 293-2100
Fax
858-436-8155
Employees
15
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$3.33
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+260.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-73,530,000.00
Net Margins
N/A
Pretax Margin
-9,030.20%
Return on Equity
-10,287.49%
Return on Assets
-209.12%

Debt

Debt-to-Equity Ratio
1.36
Current Ratio
0.60
Quick Ratio
0.60

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.10) per share
Price / Book
-9.25

Miscellaneous

Outstanding Shares
121,810,000
Free Float
114,015,000
Market Cap
$112.66 million
Optionable
Not Optionable
Beta
1.74

Social Links


Key Executives

  • Raj Mehra
    Chairman, President & Chief Executive Officer
  • Michael Golembiewski
    Chief Financial Officer
  • Timothy J. Whitaker
    Chief Medical Officer
  • Gopal Krishna
    Head-Manufacturing & Technical Operations
  • Karen Fusaro
    Senior Vice President & Head-Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SEEL Stock - Frequently Asked Questions

Should I buy or sell Seelos Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SEEL shares.
View SEEL analyst ratings or view top-rated stocks.

What is Seelos Therapeutics' stock price forecast for 2023?

1 brokers have issued twelve-month price objectives for Seelos Therapeutics' shares. Their SEEL share price forecasts range from $2.00 to $4.00. On average, they anticipate the company's share price to reach $3.33 in the next year. This suggests a possible upside of 260.4% from the stock's current price.
View analysts price targets for SEEL or view top-rated stocks among Wall Street analysts.

How have SEEL shares performed in 2023?

Seelos Therapeutics' stock was trading at $0.6790 at the start of the year. Since then, SEEL shares have increased by 36.2% and is now trading at $0.9249.
View the best growth stocks for 2023 here.

When is Seelos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our SEEL earnings forecast.

What ETF holds Seelos Therapeutics' stock ?

AdvisorShares Psychedelics ETF holds 399,133 shares of SEEL stock, representing 5.54% of its portfolio.

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK).

What is Seelos Therapeutics' stock symbol?

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

Who are Seelos Therapeutics' major shareholders?

Seelos Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Gendell Jeffrey L (4.16%), BlackRock Inc. (1.36%), Mirae Asset Global Investments Co. Ltd. (1.18%), Geode Capital Management LLC (0.93%), Uniplan Investment Counsel Inc. (0.93%) and Wealth Effects LLC (0.78%). Insiders that own company stock include Daniel J O'connor and Raj Mehra.
View institutional ownership trends.

How do I buy shares of Seelos Therapeutics?

Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seelos Therapeutics' stock price today?

One share of SEEL stock can currently be purchased for approximately $0.92.

How much money does Seelos Therapeutics make?

Seelos Therapeutics (NASDAQ:SEEL) has a market capitalization of $112.66 million.

How can I contact Seelos Therapeutics?

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The official website for the company is www.seelostherapeutics.com. The company can be reached via phone at (646) 293-2100, via email at anthony.marciano@seelostx.com, or via fax at 858-436-8155.

This page (NASDAQ:SEEL) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -